Loading
KDM5D (Lysine-specific demethylase 5D) is a protein that switches other genes on and off. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Prostate cancer.
Histone demethylase that specifically demethylates 'Lys-4' of histone H3, thereby playing a central role in histone code. Does not demethylate histone H3 'Lys-9', H3 'Lys-27', H3 'Lys-36', H3 'Lys-79' or H4 'Lys-20'. Demethylates trimethylated and dimethylated but not monomethylated H3 'Lys-4'.
CIViC holds 1 clinical evidence item and 0 assertions across 1 variant, naming Berzosertib.
In plain words · KDM5D (Lysine-specific demethylase 5D) is a protein that switches other genes on and off. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Prostate cancer.
KDM5D (Lysine-specific demethylase 5D) is a protein that switches other genes on and off. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Prostate cancer.
Histone demethylase that specifically demethylates 'Lys-4' of histone H3, thereby playing a central role in histone code. Does not demethylate histone H3 'Lys-9', H3 'Lys-27', H3 'Lys-36', H3 'Lys-79' or H4 'Lys-20'.
No product in this corpus aims at KDM5D yet. Transcription factors have no pocket to plug, so drugs either degrade them or block the partner protein they need to dock on DNA.
Broadly expressed or essential: HPA finds the RNA at low tissue specificity; a medicine acting on the wild-type protein would expose normal tissue too. HPA KDM5D: RNA low tissue specificity; no normal tissue stained high. Distribution: 1 cancer family in the corpus carries a prevalence row, label threshold or catalogue link for it (Prostate cancer); Open Targets associates it with 0 specific cancer types at or above 0.5. (Rule 7 of scripts/fetch-target-specificity.ts.)
Sources: Human Protein Atlas KDM5D tissue; Open Targets ENSG00000012817 associations
First described 1996. Earliest sequence paper UniProt cites for the protein: Kent-First M.G. et al, Nat. Genet, 1996, "Gene sequence and evolutionary conservation of human SMCY". Source.
Sources: HGNC HGNC:11115 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt Q9BY66 (protein name, function text, keywords and locations (REST API)); CIViC gene KDM5D (1 evidence items, 0 assertions, 1 variants; diseases: Prostate Cancer (GraphQL API, CC0))
Histone demethylase that specifically demethylates 'Lys-4' of histone H3, thereby playing a central role in histone code. Does not demethylate histone H3 'Lys-9', H3 'Lys-27', H3 'Lys-36', H3 'Lys-79' or H4 'Lys-20'. Demethylates trimethylated and dimethylated but not monomethylated H3 'Lys-4'. May play a role in spermatogenesis. Involved in transcriptional repression of diverse metastasis-associated genes; in this function seems to cooperate with ZMYND8. Suppresses prostate cancer cell invasion. Location: Nucleus (UniProt). Locus Yq11.223 (HGNC).
RNA: low tissue specificity, detected in many normal tissues.
No normal tissue stained high.
No cancer sample stained medium or high.
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
Query for this target: (TITLE:"KDM5D" OR ABSTRACT:"KDM5D" OR TITLE:"lysine demethylase 5D" OR ABSTRACT:"lysine demethylase 5D" OR TITLE:"Lysine-specific demethylase 5D" OR ABSTRACT:"Lysine-specific demethylase 5D" OR TITLE:"KIAA0234" OR ABSTRACT:"KIAA0234" OR TITLE:"JARID1D" OR ABSTRACT:"JARID1D") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about KDM5D, not a curated reading list.